Here's some other vaccine news of note for the week:
> As GlaxoSmithKline and Merck & Co. face supply issues that have led to global hepatitis B vaccine shortage, Dynavax has launched its recently approved Heplisav-B in the U.S. at the wholesale acquisition price of $115 per dose, or $230 per regimen. Release
> Emergent BioSolutions announced its 2018 financial guidance. It expects full-year revenues of $715 million to $755 million, up from the just amended 2017 preliminary results of between $555 million and $560 million. Release
> The WHO prequalified the first typhoid conjugate vaccine, Typbar-TCV, manufactured by India’s Bharat Biotech, making the vaccine eligible for international procurement. The vaccine can be given to young children and has longer-lasting immunity than older versions. WHO Release
> A new study published in The Lancet found PharmaJet’s needle-free injection technology could augment Zika DNA vaccine immune responses. The Lancet study